A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells

Corwin M. Nycholat, Shiteng Duan, Eva Knuplez, Charli Worth, Mila Elich, Anzhi Yao, Jeremy O'Sullivan, Ryan McBride, Yadong Wei, Steve M. Fernandes, Zhou Zhu, Ronald Lee Schnaar, Bruce S. Bochner, James C. Paulson

Research output: Contribution to journalArticle

Abstract

The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands. A key challenge for this approach is the identification of a high affinity ligand for the target Siglec. Here, we report the development of a ligand of Siglec-8 and its closest murine functional orthologue Siglec-F that is capable of targeting liposomes to cells expressing Siglec-8 or -F. A glycan microarray library of synthetic 9-N-sulfonyl sialoside analogues was screened to identify potential lead compounds. The best ligand, 9-N-(2-naphthyl-sulfonyl)-Neu5Acα2-3-[6-O-sulfo]-Galβ1-4GlcNAc (6'-O-sulfo NSANeu5Ac) combined the lead 2-naphthyl sulfonyl C-9 substituent with the preferred sulfated scaffold. The ligand 6'-O-sulfo NSANeu5Ac was conjugated to lipids for display on liposomes to evaluate targeted delivery to cells. Targeted liposomes showed strong in vitro binding/uptake and selectivity to cells expressing Siglec-8 or -F and, when administered to mice, exhibit in vivo targeting to Siglec-F+ eosinophils.

Original languageEnglish (US)
Pages (from-to)14032-14037
Number of pages6
JournalJournal of the American Chemical Society
Volume141
Issue number36
DOIs
StatePublished - Sep 11 2019

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
Sulfonamides
Ligands
Liposomes
Display devices
Cells
Lead compounds
Microarrays
Eosinophils
Scaffolds
Lipids
Lead
Nanoparticles
Cell Surface Receptors
Cell- and Tissue-Based Therapy
Mast Cells
Libraries
Polysaccharides

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Nycholat, C. M., Duan, S., Knuplez, E., Worth, C., Elich, M., Yao, A., ... Paulson, J. C. (2019). A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells. Journal of the American Chemical Society, 141(36), 14032-14037. https://doi.org/10.1021/jacs.9b05769

A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells. / Nycholat, Corwin M.; Duan, Shiteng; Knuplez, Eva; Worth, Charli; Elich, Mila; Yao, Anzhi; O'Sullivan, Jeremy; McBride, Ryan; Wei, Yadong; Fernandes, Steve M.; Zhu, Zhou; Schnaar, Ronald Lee; Bochner, Bruce S.; Paulson, James C.

In: Journal of the American Chemical Society, Vol. 141, No. 36, 11.09.2019, p. 14032-14037.

Research output: Contribution to journalArticle

Nycholat, CM, Duan, S, Knuplez, E, Worth, C, Elich, M, Yao, A, O'Sullivan, J, McBride, R, Wei, Y, Fernandes, SM, Zhu, Z, Schnaar, RL, Bochner, BS & Paulson, JC 2019, 'A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells', Journal of the American Chemical Society, vol. 141, no. 36, pp. 14032-14037. https://doi.org/10.1021/jacs.9b05769
Nycholat, Corwin M. ; Duan, Shiteng ; Knuplez, Eva ; Worth, Charli ; Elich, Mila ; Yao, Anzhi ; O'Sullivan, Jeremy ; McBride, Ryan ; Wei, Yadong ; Fernandes, Steve M. ; Zhu, Zhou ; Schnaar, Ronald Lee ; Bochner, Bruce S. ; Paulson, James C. / A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells. In: Journal of the American Chemical Society. 2019 ; Vol. 141, No. 36. pp. 14032-14037.
@article{a58c18f8e6ad4f14bd78336054233307,
title = "A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells",
abstract = "The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands. A key challenge for this approach is the identification of a high affinity ligand for the target Siglec. Here, we report the development of a ligand of Siglec-8 and its closest murine functional orthologue Siglec-F that is capable of targeting liposomes to cells expressing Siglec-8 or -F. A glycan microarray library of synthetic 9-N-sulfonyl sialoside analogues was screened to identify potential lead compounds. The best ligand, 9-N-(2-naphthyl-sulfonyl)-Neu5Acα2-3-[6-O-sulfo]-Galβ1-4GlcNAc (6'-O-sulfo NSANeu5Ac) combined the lead 2-naphthyl sulfonyl C-9 substituent with the preferred sulfated scaffold. The ligand 6'-O-sulfo NSANeu5Ac was conjugated to lipids for display on liposomes to evaluate targeted delivery to cells. Targeted liposomes showed strong in vitro binding/uptake and selectivity to cells expressing Siglec-8 or -F and, when administered to mice, exhibit in vivo targeting to Siglec-F+ eosinophils.",
author = "Nycholat, {Corwin M.} and Shiteng Duan and Eva Knuplez and Charli Worth and Mila Elich and Anzhi Yao and Jeremy O'Sullivan and Ryan McBride and Yadong Wei and Fernandes, {Steve M.} and Zhou Zhu and Schnaar, {Ronald Lee} and Bochner, {Bruce S.} and Paulson, {James C.}",
year = "2019",
month = "9",
day = "11",
doi = "10.1021/jacs.9b05769",
language = "English (US)",
volume = "141",
pages = "14032--14037",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "36",

}

TY - JOUR

T1 - A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells

AU - Nycholat, Corwin M.

AU - Duan, Shiteng

AU - Knuplez, Eva

AU - Worth, Charli

AU - Elich, Mila

AU - Yao, Anzhi

AU - O'Sullivan, Jeremy

AU - McBride, Ryan

AU - Wei, Yadong

AU - Fernandes, Steve M.

AU - Zhu, Zhou

AU - Schnaar, Ronald Lee

AU - Bochner, Bruce S.

AU - Paulson, James C.

PY - 2019/9/11

Y1 - 2019/9/11

N2 - The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands. A key challenge for this approach is the identification of a high affinity ligand for the target Siglec. Here, we report the development of a ligand of Siglec-8 and its closest murine functional orthologue Siglec-F that is capable of targeting liposomes to cells expressing Siglec-8 or -F. A glycan microarray library of synthetic 9-N-sulfonyl sialoside analogues was screened to identify potential lead compounds. The best ligand, 9-N-(2-naphthyl-sulfonyl)-Neu5Acα2-3-[6-O-sulfo]-Galβ1-4GlcNAc (6'-O-sulfo NSANeu5Ac) combined the lead 2-naphthyl sulfonyl C-9 substituent with the preferred sulfated scaffold. The ligand 6'-O-sulfo NSANeu5Ac was conjugated to lipids for display on liposomes to evaluate targeted delivery to cells. Targeted liposomes showed strong in vitro binding/uptake and selectivity to cells expressing Siglec-8 or -F and, when administered to mice, exhibit in vivo targeting to Siglec-F+ eosinophils.

AB - The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands. A key challenge for this approach is the identification of a high affinity ligand for the target Siglec. Here, we report the development of a ligand of Siglec-8 and its closest murine functional orthologue Siglec-F that is capable of targeting liposomes to cells expressing Siglec-8 or -F. A glycan microarray library of synthetic 9-N-sulfonyl sialoside analogues was screened to identify potential lead compounds. The best ligand, 9-N-(2-naphthyl-sulfonyl)-Neu5Acα2-3-[6-O-sulfo]-Galβ1-4GlcNAc (6'-O-sulfo NSANeu5Ac) combined the lead 2-naphthyl sulfonyl C-9 substituent with the preferred sulfated scaffold. The ligand 6'-O-sulfo NSANeu5Ac was conjugated to lipids for display on liposomes to evaluate targeted delivery to cells. Targeted liposomes showed strong in vitro binding/uptake and selectivity to cells expressing Siglec-8 or -F and, when administered to mice, exhibit in vivo targeting to Siglec-F+ eosinophils.

UR - http://www.scopus.com/inward/record.url?scp=85072012916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072012916&partnerID=8YFLogxK

U2 - 10.1021/jacs.9b05769

DO - 10.1021/jacs.9b05769

M3 - Article

VL - 141

SP - 14032

EP - 14037

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 36

ER -